Resverlogix Corp. (FRA:RFS)

Germany flag Germany · Delayed Price · Currency is EUR
0.0600
-0.0010 (-1.64%)
Last updated: Jan 28, 2026, 8:02 AM CET
66.67%
Market Cap18.75M +79.5%
Revenue (ttm)n/a
Net Income-6.05M
EPS-0.02
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume250
Open0.0600
Previous Close0.0610
Day's Range0.0600 - 0.0600
52-Week Range0.0190 - 0.1580
Betan/a
RSI49.28
Earnings DateMar 26, 2026

About Resverlogix

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Donald McCaffrey
Employees 19
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RFS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements